Company news
Enveric Biosciences, Inc. news in 2024
Enveric Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
December 1, 2024
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
November 24, 2024
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
November 13, 2024
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
November 11, 2024
Enveric Biosciences Announces Broad Range of Patent Issuances
November 3, 2024
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
October 14, 2024
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
September 24, 2024
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
August 11, 2024
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
July 24, 2024
Enveric Biosciences Announces Patent Granted for Drug Candidate
July 9, 2024
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
June 24, 2024
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
May 14, 2024
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
May 7, 2024
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
March 25, 2024
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
March 18, 2024
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
March 11, 2024
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
February 22, 2024
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
February 20, 2024
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
January 2, 2024
Decks in 2024
- Investor Presentation (August 2024)
Investor deck · 15 slides · Aug 22, 2024